These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12591081)

  • 1. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF.
    Holtmann MH; Galle PR; Neurath MF
    Am J Gastroenterol; 2003 Feb; 98(2):504-5. PubMed ID: 12591081
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center].
    Dotan I; Yeshurun D; Hallak A; Horowitz N; Tiomny E; Reif S; Halpern Z; Rachmilewitz D
    Harefuah; 2001 Apr; 140(4):289-93, 368. PubMed ID: 11303390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [What can be expected from biological therapies for Crohn's disease?].
    Lemann M
    Gastroenterol Clin Biol; 2001 Nov; 25(11):945-7. PubMed ID: 11845043
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.
    Suenaert P; Bulteel V; Lemmens L; Noman M; Geypens B; Van Assche G; Geboes K; Ceuppens JL; Rutgeerts P
    Am J Gastroenterol; 2002 Aug; 97(8):2000-4. PubMed ID: 12190167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytomegalovirus primary infection in a patient with Crohn's disease treated with azathioprine and anti-TNF alpha].
    Ben Hriz F; Habbessi H; Maamouri N; Belkahla N; Ouerdiane S; Chouaib S; Ouerghi H; Chaabouni H; Ben Mami N
    Tunis Med; 2009 Aug; 87(8):545-6. PubMed ID: 20180364
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biological compounds in the treatment of Crohn's disease].
    Dinari G
    Harefuah; 2001 Apr; 140(4):316-8. PubMed ID: 11303396
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease.
    Abdelmalek MF; Liu C; Valentine JF
    Am J Gastroenterol; 2007 Jun; 102(6):1333-4. PubMed ID: 17531027
    [No Abstract]   [Full Text] [Related]  

  • 11. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease.
    Tsujikawa T; Nezu R; Andoh A; Saotome T; Araki Y; Ishizuka Y; Sasaki M; Koyama S; Fujiyama Y
    J Gastroenterol; 2004; 39(3):284-7. PubMed ID: 15065007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Infliximab--practical guidelines for the treatment of Crohn's disease].
    Bauerfeind P; Beglinger C; Beltinger J; Braegger C; Eigenmann F; Fried M; Guyot J; Hürlimann R; Michetti P; Seibold F; Straumann A
    Rev Med Suisse; 2006 Jul; 2(74):1807-15. PubMed ID: 16927560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
    Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
    Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of response to infliximab in Crohn's disease.
    Chaudhary R; Ghosh S
    Dig Liver Dis; 2005 Aug; 37(8):559-63. PubMed ID: 15893967
    [No Abstract]   [Full Text] [Related]  

  • 17. Closing fistulas in Crohn's disease--should the accent be on maintenance or safety?
    Fiocchi C
    N Engl J Med; 2004 Feb; 350(9):934-6. PubMed ID: 14985492
    [No Abstract]   [Full Text] [Related]  

  • 18. Infliximab in the management of the extra-intestinal manifestations of Crohn's disease.
    Lawrance IC
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1332-3. PubMed ID: 15482549
    [No Abstract]   [Full Text] [Related]  

  • 19. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment.
    Zeissig S; Bojarski C; Buergel N; Mankertz J; Zeitz M; Fromm M; Schulzke JD
    Gut; 2004 Sep; 53(9):1295-302. PubMed ID: 15306588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.